Reyataz
Glaxo to test rival’s protease inhibitor, re-engineered to last longer
Thursday, June 4th, 2009Source: AidsMap.com
GlaxoSmithKline announced today that it has signed a development deal with Concert Pharmaceuticals for a new protease inhibitor, engineered to avoid the need for any sort of boosting agent.
CTP-518 is a modified form of the HIV protease inhibitor atazanavir in which key hydrogen atoms have been replaced by deuterium, a heavier relative of hydrogen. [...]
